NCT05872126

Brief Summary

Malignant Pleural Effusion (MPE) is considered to be a common presentation at malignant tumors representing 15% of all cancer cases. It carries a burden on our patients with dyspnea being the most common symptom in most of cases. Management of symptomatic malignant pleural effusion remains to be a point of debate. Data available from literature shows conflicting results lacking high quality evidence which necsscitates further research work. Options differs to include chemical pleurodesis using medical or surgical talc poudrage or slurry. Surgical intervention with abrasion pleurodesis or pleurectomy using VATS approach has been used in many studies. Using indwelling pleural catheters (IPCs) has also proved comparable efficacy at many clinical trials. In this study we want to help answering this question so that we can add to the current knowledge aiming to offer the best care for those patients

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

May 13, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

May 24, 2023

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2025

Completed
Last Updated

May 24, 2023

Status Verified

May 1, 2023

Enrollment Period

2 years

First QC Date

May 13, 2023

Last Update Submit

May 22, 2023

Conditions

Keywords

Malignant pleural effusionVATSPleurXAbrasion

Outcome Measures

Primary Outcomes (2)

  • Total hospital stay

    duration of hospital stay in days

    3 months postoperative

  • duration of airleak

    duration in days

    3 months postoperative

Secondary Outcomes (3)

  • Status of performance

    3 months

  • mortality

    '3 months

  • Failure of management

    3 months

Study Arms (2)

VATS surgical pleurodesis

OTHER

Patients in whom we use VATS-surgical pleurodesis for malignant pleural effusion.

Procedure: VATS-Surgical pleurodesis

Tube drainage

OTHER

Patients in whom we use tube drainage for malignant pleural effusion.

Procedure: Tube Drainage

Interventions

VATS drainage and surgical abrasion.

VATS surgical pleurodesis
Tube DrainagePROCEDURE

Tube drainage for malignant pleural effusion

Tube drainage

Eligibility Criteria

Age5 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • patients with symptomatic malignant pleural effusion. 2- symptomatic patients with shortness of breath. 3-Lung can be fully expanded.

You may not qualify if:

  • Patients with non symptomatic malignant pleural effusion
  • Pleural symphysis with no potentiality for re-expansion
  • Patients managed surgically through open thoracotomy.
  • Pleural effusion due to causes other than malignancy
  • Loculated malignant effusion judged by chest ultrasound
  • Trapped lung due to malignant pleural effusion assessed by multislice CT chest.,
  • Refusal to share the research project and not to sign the consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut university heart hospital

Asyut, 2112, Egypt

RECRUITING

MeSH Terms

Conditions

Pleural Effusion, Malignant

Condition Hierarchy (Ancestors)

Pleural NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsPleural EffusionPleural DiseasesRespiratory Tract Diseases

Central Study Contacts

Kareem A Hosny, M.SC

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomised Clinical Trial with 2 groups; Case group for VATS mechanical abrasion and Control group for tube drainage
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle investigator

Study Record Dates

First Submitted

May 13, 2023

First Posted

May 24, 2023

Study Start

April 1, 2023

Primary Completion

March 31, 2025

Study Completion

April 30, 2025

Last Updated

May 24, 2023

Record last verified: 2023-05

Locations